129 related articles for article (PubMed ID: 32003046)
1. PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Gotoh N; Minato Y; Saitoh T; Takahashi N; Kasamatsu T; Souma K; Oda T; Hoshino T; Sakura T; Ishizaki T; Shimizu H; Takizawa M; Yokohama A; Tsukamoto N; Handa H; Murakami H
Eur J Haematol; 2020 Jun; 104(6):526-537. PubMed ID: 32003046
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT; Kontandreopoulou CN; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Vassilakopoulos T; Dimou M; Solomou E; Kyrtsonis MC; Siakantaris M; Angelopoulou M; Kourakli A; Papageorgiou S; Christopoulou G; Roumelioti M; Panayiotidis P; Viniou NA;
Ann Hematol; 2019 Jun; 98(6):1383-1392. PubMed ID: 30877373
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
Diamantopoulos P; Zervakis K; Zervakis P; Sofotasiou M; Vassilakopoulos T; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Solomou E; Kodandreopoulou E; Papadopoulou V; Korkolopoulou P; Mantzourani M; Kyriakakis G; Viniou NA
Blood Cancer J; 2017 Feb; 7(2):e533. PubMed ID: 28212373
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome.
Kasamatsu T; Saitoh T; Minato Y; Shimizu H; Yokohama A; Tsukamoto N; Handa H; Sakura T; Murakami H
Eur J Haematol; 2016 Mar; 96(3):245-51. PubMed ID: 25941112
[TBL] [Abstract][Full Text] [Related]
5. [Study on HFE gene mutations in patients with myelodysplastic syndromes and aplastic anemia].
Nie L; Ai XF; Zheng YZ; Li QH; Yang L; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):223-8. PubMed ID: 19731820
[TBL] [Abstract][Full Text] [Related]
6. GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.
Botezatu L; Michel LC; Makishima H; Schroeder T; Germing U; Haas R; van der Reijden B; Marneth AE; Bergevoet SM; Jansen JH; Przychodzen B; Wlodarski M; Niemeyer C; Platzbecker U; Ehninger G; Unnikrishnan A; Beck D; Pimanda J; Hellström-Lindberg E; Malcovati L; Boultwood J; Pellagatti A; Papaemmanuil E; Le Coutre P; Kaeda J; Opalka B; Möröy T; Dührsen U; Maciejewski J; Khandanpour C
Exp Hematol; 2016 Jul; 44(7):590-595.e1. PubMed ID: 27080012
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.
Gonçalves AC; Alves R; Baldeiras I; Cortesão E; Carda JP; Branco CC; Oliveiros B; Loureiro L; Pereira A; Nascimento Costa JM; Sarmento-Ribeiro AB; Mota-Vieira L
Mol Carcinog; 2017 Jan; 56(1):130-148. PubMed ID: 26950655
[TBL] [Abstract][Full Text] [Related]
10. MDR-1 and GST polymorphisms are involved in myelodysplasia progression.
Palodetto B; de Melo Campos P; Benites BD; de Lourdes Lopes Ferrari Chauffaille M; Velloso ED; Traina F; Saad ST
Leuk Res; 2013 Aug; 37(8):970-3. PubMed ID: 23684483
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients.
Chaubey R; Sazawal S; Mahapatra M; Chhikara S; Saxena R
Int J Lab Hematol; 2015 Apr; 37(2):265-71. PubMed ID: 25123164
[TBL] [Abstract][Full Text] [Related]
12. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts.
Nearman ZP; Szpurka H; Serio B; Warshawksy I; Theil K; Lichtin A; Sekeres MA; Maciejewski JP
Am J Hematol; 2007 Dec; 82(12):1076-9. PubMed ID: 17654685
[TBL] [Abstract][Full Text] [Related]
13. Clinical importance of transforming growth factor-beta but not of tumor necrosis factor-alpha gene polymorphisms in patients with the myelodysplastic syndrome belonging to the refractory anemia subtype.
Balog A; Borbényi Z; Gyulai Z; Molnár L; Mándi Y
Pathobiology; 2005; 72(3):165-70. PubMed ID: 15860935
[TBL] [Abstract][Full Text] [Related]
14. Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.
Nogueira A; Assis J; Faustino I; Pereira D; Catarino R; Medeiros R
Biomarkers; 2017 Feb; 22(1):70-76. PubMed ID: 27323894
[TBL] [Abstract][Full Text] [Related]
15. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
Ma W; Kantarjian H; Zhang K; Zhang X; Wang X; Chen C; Donahue AC; Zhang Z; Yeh CH; O'Brien S; Garcia-Manero G; Caporaso N; Landgren O; Albitar M
BMC Med Genet; 2010 Nov; 11():163. PubMed ID: 21078205
[TBL] [Abstract][Full Text] [Related]
16. Association of A(313)G glutathione S-transferase P1 germline polymorphism with susceptibility to de novo myelodysplastic syndrome.
Zachaki S; Stavropoulou C; Kalomoiraki M; Koromila T; Daraki A; Manola KN; Mavrou A; Kanavakis E; Pantelias GE; Sambani C
Leuk Lymphoma; 2013 Aug; 54(8):1756-61. PubMed ID: 23278642
[TBL] [Abstract][Full Text] [Related]
17. New polymorphisms of Xeroderma Pigmentosum DNA repair genes in myelodysplastic syndrome.
Santiago SP; Junior HLR; de Sousa JC; de Paula Borges D; de Oliveira RTG; Farias IR; Costa MB; Maia ARS; da Nóbrega Ito M; Magalhães SMM; Pinheiro RF
Leuk Res; 2017 Jul; 58():73-82. PubMed ID: 28472728
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of GSTT1, GSTM1 and NQO1 genes polymorphisms in myelodysplastic syndromes].
Yang L; Zou X; Zhang MR; Zhang Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):674-7. PubMed ID: 16620556
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
Zhai L; Li S; Li H; Zheng Y; Lang R; Fan Y; Gu F; Guo X; Zhang X; Fu L
Int J Clin Exp Pathol; 2015; 8(6):7059-71. PubMed ID: 26261599
[TBL] [Abstract][Full Text] [Related]
20. Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.
Yu H; Ma H; Yin M; Wei Q
Genet Epidemiol; 2012 Jan; 36(1):56-65. PubMed ID: 22127734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
